Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions.

Gawronski AR, Uhl M, Zhang Y, Lin YY, Niknafs YS, Ramnarine VR, Malik R, Feng F, Chinnaiyan AM, Collins CC, Sahinalp SC, Backofen R.

Bioinformatics. 2018 Apr 3. doi: 10.1093/bioinformatics/bty208. [Epub ahead of print]

PMID:
29617966
2.

Heterochromatin protein 1α mediates development and aggressiveness of neuroendocrine prostate cancer.

Ci X, Hao J, Dong X, Choi SYC, Xue H, Wu R, Qu S, Gout PW, Zhang F, Haegert AM, Fazil L, Crea F, Ong CJ, Zoubedi A, He HH, Gleave ME, Collins CC, Lin D, Wang Y.

Cancer Res. 2018 Feb 27. pii: canres.3677.2017. doi: 10.1158/0008-5472.CAN-17-3677. [Epub ahead of print]

PMID:
29487201
3.

Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.

Qu S, Xue H, Dong X, Lin D, Wu R, Nabavi N, Collins CC, Gleave ME, Gout PW, Wang Y.

Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31310. [Epub ahead of print]

PMID:
29441566
4.

Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.

Qu S, Ci X, Xue H, Dong X, Hao J, Lin D, Clermont PL, Wu R, Collins CC, Gout PW, Wang Y.

Br J Cancer. 2018 Mar 20;118(6):802-812. doi: 10.1038/bjc.2017.474. Epub 2018 Jan 30.

5.

Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia.

Melong N, Steele S, MacDonald M, Holly A, Collins CC, Zoubeidi A, Berman JN, Dellaire G.

Sci Rep. 2017 Oct 31;7(1):14698. doi: 10.1038/s41598-017-14413-w.

6.

Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer.

Kalina JL, Neilson DS, Lin YY, Hamilton PT, Comber AP, Loy EMH, Sahinalp SC, Collins CC, Hach F, Lum JJ.

Clin Cancer Res. 2017 Dec 15;23(24):7596-7607. doi: 10.1158/1078-0432.CCR-17-0618. Epub 2017 Sep 27.

PMID:
28954787
7.

Paid sick leave and psychological distress: An analysis of U.S. workers.

Stoddard-Dare P, DeRigne L, Collins CC, Quinn LM, Fuller K.

Am J Orthopsychiatry. 2018;88(1):1-9. doi: 10.1037/ort0000293. Epub 2017 Sep 14.

PMID:
28910124
8.

A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.

Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, Wang Y, Demichelis F, Beltran H, Rubin MA, Rickman DS.

Cold Spring Harb Mol Case Stud. 2017 Sep;3(5). pii: a001487. doi: 10.1101/mcs.a001487. Epub 2017 May 3.

9.

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.

Beltran H, Wyatt AW, Chedgy EC, Donoghue A, Annala M, Warner EW, Beja K, Sigouros M, Mo F, Fazli L, Collins CC, Eastham J, Morris M, Taplin ME, Sboner A, Halabi S, Gleave ME.

Clin Cancer Res. 2017 Nov 15;23(22):6802-6811. doi: 10.1158/1078-0432.CCR-17-1034. Epub 2017 Aug 25.

PMID:
28842510
10.

HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology.

Shrestha R, Hodzic E, Sauerwald T, Dao P, Wang K, Yeung J, Anderson S, Vandin F, Haffari G, Collins CC, Sahinalp SC.

Genome Res. 2017 Sep;27(9):1573-1588. doi: 10.1101/gr.221218.117. Epub 2017 Jul 18.

11.

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.

Vandekerkhove G, Todenhöfer T, Annala M, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW.

Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. doi: 10.1158/1078-0432.CCR-17-1140. Epub 2017 Jul 31.

PMID:
28760909
12.

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer.

Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y.

Oncotarget. 2017 Apr 18;8(16):25928-25941. doi: 10.18632/oncotarget.15237.

13.

Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.

Lee AR, Li Y, Xie N, Gleave ME, Cox ME, Collins CC, Dong X.

Oncotarget. 2017 Apr 25;8(17):27966-27975. doi: 10.18632/oncotarget.15854.

14.

Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.

Mo F, Lin D, Takhar M, Ramnarine VR, Dong X, Bell RH, Volik SV, Wang K, Xue H, Wang Y, Haegert A, Anderson S, Brahmbhatt S, Erho N, Wang X, Gout PW, Morris J, Karnes RJ, Den RB, Klein EA, Schaeffer EM, Ross A, Ren S, Sahinalp SC, Li Y, Xu X, Wang J, Wang J, Gleave ME, Davicioni E, Sun Y, Wang Y, Collins CC.

Eur Urol. 2018 Apr;73(4):524-532. doi: 10.1016/j.eururo.2017.02.038. Epub 2017 Mar 19.

PMID:
28330676
15.

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.

Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L.

Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. Review.

16.

Genomic hallmarks of localized, non-indolent prostate cancer.

Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, Ahmed M, Trudel D, Luo X, Beck TA, Meng A, Zhang J, D'Costa A, Denroche RE, Kong H, Espiritu SM, Chua ML, Wong A, Chong T, Sam M, Johns J, Timms L, Buchner NB, Orain M, Picard V, Hovington H, Murison A, Kron K, Harding NJ, P'ng C, Houlahan KE, Chu KC, Lo B, Nguyen F, Li CH, Sun RX, de Borja R, Cooper CI, Hopkins JF, Govind SK, Fung C, Waggott D, Green J, Haider S, Chan-Seng-Yue MA, Jung E, Wang Z, Bergeron A, Dal Pra A, Lacombe L, Collins CC, Sahinalp C, Lupien M, Fleshner NE, He HH, Fradet Y, Tetu B, van der Kwast T, McPherson JD, Bristow RG, Boutros PC.

Nature. 2017 Jan 19;541(7637):359-364. doi: 10.1038/nature20788. Epub 2017 Jan 9.

PMID:
28068672
17.

Clonality Inference from Single Tumor Samples Using Low-Coverage Sequence Data.

Donmez N, Malikic S, Wyatt AW, Gleave ME, Collins CC, Sahinalp SC.

J Comput Biol. 2017 Jun;24(6):515-523. doi: 10.1089/cmb.2016.0148. Epub 2017 Jan 5.

PMID:
28056180
18.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

19.

BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer.

Luk IS, Shrestha R, Xue H, Wang Y, Zhang F, Lin D, Haegert A, Wu R, Dong X, Collins CC, Zoubeidi A, Gleave ME, Gout PW, Wang Y.

Clin Cancer Res. 2017 Mar 15;23(6):1542-1551. doi: 10.1158/1078-0432.CCR-16-0718. Epub 2016 Sep 23.

20.

Framing Young Childrens Oral Health: A Participatory Action Research Project.

Collins CC, Villa-Torres L, Sams LD, Zeldin LP, Divaris K.

PLoS One. 2016 Aug 22;11(8):e0161728. doi: 10.1371/journal.pone.0161728. eCollection 2016.

21.

SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.

Kockan C, Hach F, Sarrafi I, Bell RH, McConeghy B, Beja K, Haegert A, Wyatt AW, Volik SV, Chi KN, Collins CC, Sahinalp SC.

Bioinformatics. 2017 Jan 1;33(1):26-34. doi: 10.1093/bioinformatics/btw536. Epub 2016 Aug 16.

PMID:
27531099
22.

Non-targeted Metabolomics in Diverse Sorghum Breeding Lines Indicates Primary and Secondary Metabolite Profiles Are Associated with Plant Biomass Accumulation and Photosynthesis.

Turner MF, Heuberger AL, Kirkwood JS, Collins CC, Wolfrum EJ, Broeckling CD, Prenni JE, Jahn CE.

Front Plant Sci. 2016 Jul 11;7:953. doi: 10.3389/fpls.2016.00953. eCollection 2016.

23.

Necroptosis of Dendritic Cells Promotes Activation of γδ T Cells.

Collins CC, Bashant K, Erikson C, Thwe PM, Fortner KA, Wang H, Morita CT, Budd RC.

J Innate Immun. 2016;8(5):479-92. doi: 10.1159/000446498. Epub 2016 Jul 19.

24.

Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.

Chedgy EC, Douglas J, Wright JL, Seiler R, van Rhijn BW, Boormans J, Todenhöfer T, Dinney CP, Collins CC, Van der Heijden MS, Black PC.

Urol Oncol. 2016 Oct;34(10):469-76. doi: 10.1016/j.urolonc.2016.05.012. Epub 2016 Jun 15. Review.

PMID:
27317490
25.

Transcriptome-Based Analysis of Molecular Pathways for Clusterin Functions in Kidney Cells.

Dairi G, Guan Q, Roshan-Moniri M, Collins CC, Ong CJ, Gleave ME, Nguan CY, Du C.

J Cell Physiol. 2016 Dec;231(12):2628-38. doi: 10.1002/jcp.25415. Epub 2016 Jun 15.

PMID:
27155085
26.

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN.

JAMA Oncol. 2016 Dec 1;2(12):1598-1606. doi: 10.1001/jamaoncol.2016.0494.

27.

The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells.

Labrecque MP, Takhar MK, Nason R, Santacruz S, Tam KJ, Massah S, Haegert A, Bell RH, Altamirano-Dimas M, Collins CC, Lee FJ, Prefontaine GG, Cox ME, Beischlag TV.

Oncotarget. 2016 Apr 26;7(17):24284-302. doi: 10.18632/oncotarget.8301.

28.

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer.

Clermont PL, Crea F, Chiang YT, Lin D, Zhang A, Wang JZ, Parolia A, Wu R, Xue H, Wang Y, Ding J, Thu KL, Lam WL, Shah SP, Collins CC, Wang Y, Helgason CD.

Clin Epigenetics. 2016 Feb 12;8:16. doi: 10.1186/s13148-016-0182-9. eCollection 2016.

29.

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.

Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A.

Genome Biol. 2016 Jan 26;17:10. doi: 10.1186/s13059-015-0864-1.

30.

The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.

Choi SY, Xue H, Wu R, Fazli L, Lin D, Collins CC, Gleave ME, Gout PW, Wang Y.

Clin Cancer Res. 2016 Jun 1;22(11):2721-33. doi: 10.1158/1078-0432.CCR-15-1624. Epub 2016 Jan 11.

31.

The Proteome of Primary Prostate Cancer.

Iglesias-Gato D, Wikström P, Tyanova S, Lavallee C, Thysell E, Carlsson J, Hägglöf C, Cox J, Andrén O, Stattin P, Egevad L, Widmark A, Bjartell A, Collins CC, Bergh A, Geiger T, Mann M, Flores-Morales A.

Eur Urol. 2016 May;69(5):942-52. doi: 10.1016/j.eururo.2015.10.053. Epub 2015 Dec 2.

PMID:
26651926
32.

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin MA, Beltran H, Zoubeidi A, Wang Y, Gleave ME, Collins CC.

Cell Rep. 2015 Aug 11;12(6):922-36. doi: 10.1016/j.celrep.2015.07.012. Epub 2015 Jul 30.

33.

Spatial genomic heterogeneity within localized, multifocal prostate cancer.

Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, Beck TA, Have CL, Chong T, Sam M, Johns J, Timms L, Buchner N, Wong A, Watson JD, Simmons TT, P'ng C, Zafarana G, Nguyen F, Luo X, Chu KC, Prokopec SD, Sykes J, Dal Pra A, Berlin A, Brown A, Chan-Seng-Yue MA, Yousif F, Denroche RE, Chong LC, Chen GM, Jung E, Fung C, Starmans MH, Chen H, Govind SK, Hawley J, D'Costa A, Pintilie M, Waggott D, Hach F, Lambin P, Muthuswamy LB, Cooper C, Eeles R, Neal D, Tetu B, Sahinalp C, Stein LD, Fleshner N, Shah SP, Collins CC, Hudson TJ, McPherson JD, van der Kwast T, Bristow RG.

Nat Genet. 2015 Jul;47(7):736-45. doi: 10.1038/ng.3315. Epub 2015 May 25.

PMID:
26005866
34.

Polycomb-mediated silencing in neuroendocrine prostate cancer.

Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Collins CC, Wang Y, Helgason CD.

Clin Epigenetics. 2015 Apr 3;7:40. doi: 10.1186/s13148-015-0074-4. eCollection 2015.

35.

The epigenetic/noncoding origin of tumor dormancy.

Crea F, Nur Saidy NR, Collins CC, Wang Y.

Trends Mol Med. 2015 Apr;21(4):206-11. doi: 10.1016/j.molmed.2015.02.005. Epub 2015 Mar 11.

PMID:
25771096
36.

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN.

Clin Cancer Res. 2015 May 15;21(10):2315-24. doi: 10.1158/1078-0432.CCR-14-2666. Epub 2015 Feb 23.

37.

Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.

Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, Gleave M.

Clin Cancer Res. 2015 Apr 1;21(7):1675-87. doi: 10.1158/1078-0432.CCR-14-1108. Epub 2015 Jan 29.

38.

Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.

Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, Brahmbhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave ME, Collins CC, Wang Y.

Oncotarget. 2015 Jan 30;6(3):1806-20.

39.

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.

Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DY, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG.

Lancet Oncol. 2014 Dec;15(13):1521-32. doi: 10.1016/S1470-2045(14)71021-6. Epub 2014 Nov 13.

40.

Lessons from patient-derived xenografts for better in vitro modeling of human cancer.

Choi SY, Lin D, Gout PW, Collins CC, Xu Y, Wang Y.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:222-37. doi: 10.1016/j.addr.2014.09.009. Epub 2014 Oct 13. Review.

41.

Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.

Wyatt AW, Mo F, Wang K, McConeghy B, Brahmbhatt S, Jong L, Mitchell DM, Johnston RL, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk AV, McPherson A, Shukin R, Bell RH, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan AM, Mehra R, Lin D, Wang Y, Fazli L, Gleave ME, Volik SV, Collins CC.

Genome Biol. 2014 Aug 26;15(8):426. doi: 10.1186/s13059-014-0426-y.

42.

The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.

Luk SU, Xue H, Cheng H, Lin D, Gout PW, Fazli L, Collins CC, Gleave ME, Wang Y.

Oncotarget. 2014 Aug 30;5(16):6896-908.

43.

Systematic identification and characterization of RNA editing in prostate tumors.

Mo F, Wyatt AW, Sun Y, Brahmbhatt S, McConeghy BJ, Wu C, Wang Y, Gleave ME, Volik SV, Collins CC.

PLoS One. 2014 Jul 18;9(7):e101431. doi: 10.1371/journal.pone.0101431. eCollection 2014.

44.

A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines.

Wang K, Shrestha R, Wyatt AW, Reddy A, Lehár J, Wang Y, Lapuk A, Collins CC.

PLoS One. 2014 Jul 18;9(7):e103050. doi: 10.1371/journal.pone.0103050. eCollection 2014.

45.

The role of mRNA splicing in prostate cancer.

Lapuk AV, Volik SV, Wang Y, Collins CC.

Asian J Androl. 2014 Jul-Aug;16(4):515-21. doi: 10.4103/1008-682X.127825. Review.

46.

ShatterProof: operational detection and quantification of chromothripsis.

Govind SK, Zia A, Hennings-Yeomans PH, Watson JD, Fraser M, Anghel C, Wyatt AW, van der Kwast T, Collins CC, McPherson JD, Bristow RG, Boutros PC.

BMC Bioinformatics. 2014 Mar 19;15:78. doi: 10.1186/1471-2105-15-78.

47.

Next generation patient-derived prostate cancer xenograft models.

Lin D, Xue H, Wang Y, Wu R, Watahiki A, Dong X, Cheng H, Wyatt AW, Collins CC, Gout PW, Wang Y.

Asian J Androl. 2014 May-Jun;16(3):407-12. doi: 10.4103/1008-682X.125394. No abstract available.

48.

Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification.

Chiang YT, Gout PW, Collins CC, Wang Y.

Asian J Androl. 2014 Jul-Aug;16(4):545-8. doi: 10.4103/1008-682X.122875.

49.

IL-15 maintains T-cell survival via S-nitrosylation-mediated inhibition of caspase-3.

Saligrama PT, Fortner KA, Secinaro MA, Collins CC, Russell JQ, Budd RC.

Cell Death Differ. 2014 Jun;21(6):904-14. doi: 10.1038/cdd.2014.10. Epub 2014 Feb 7.

50.

GATA2 as a potential metastasis-driving gene in prostate cancer.

Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang Y.

Oncotarget. 2014 Jan 30;5(2):451-61.

Supplemental Content

Loading ...
Support Center